FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

The FDA ap­proved Bridge­Bio’s ​​aco­ramidis in a rare, ge­net­ic heart dis­ease that’s ex­pect­ed to be­come an in­tense area of mar­ket com­pe­ti­tion, and a broad la­bel …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER